Genzyme and Cystic Fibrosis Foundation Therapeutics, Inc. have entered a research agreement for the discovery of new drugs to treat the most common mutation found in patients with CF, Delta F508. The companies will focus on identifying compounds known as “correctors,” which may help the malfunctioning CFTR protein found in CF patients to operate correctly. Researchers will evaluate different compounds for correctors for Delta F508 using compound libraries of both Genzyme and its parent company,...